Biology Reference
In-Depth Information
Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, Hanauer SB
(2007) A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative
colitis. Gastroenterology 132:76-86
Shichijo M, Inagaki N, Nakai N, Kimata M, Nakahata T, Serizawa I, Iikura Y, Saito H, Nagai H
(1998) The effects of anti-asthma drugs on mediator release from cultured human mast cells.
Clin Exp Allergy 28:1228-1236
Shore A, Dosch H, Gelfand EW (1978) Induction and separation of antigen-dependent T helper
and T suppressor cells in man. Nature 274:586-587
Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ (2010) The inhaled phosphodiester-
ase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res
11:26-35
Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA (2003)
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Am J Physiol Lung Cell Mol Physiol 284:L279-L289
Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ,
Barnette MS, Giembycz MA (2004) Discovery of BRL 50481 [3-(N, N-dimethylsulfona-
mido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies
in human monocytes,
lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol
66:1679-1689
Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Drugs 63:2575-2594
Spina D (2004) The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets
Inflamm Allergy 3:231-236
Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308-315
Spina D, Harrison S, Page CP (1995) Regulation by phosphodiesterase isoenzymes of non-
adrenergic non- cholinergic contraction in guinea-pig isolated main bronchus. Br J Pharmacol
116:2334-2340
Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J (1994) Anti-inflammatory effects of
low-dose oral theophylline in atopic asthma [published erratum appears in Lancet 1994 Jun 11;
343(8911):1512]. Lancet 343:1006-1008
Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS (1999) Chronic antidepres-
sant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B
isoforms. J Neurosci 19:610-618
Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheuma-
toid arthritis. Nat Rev Rheumatol 5:578-582
Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A (2002) Phosphodiesterase
isoenzyme families in human osteoarthritis chondrocytes-functional importance of phospho-
diesterase 4. Br J Pharmacol 135:609-618
Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T, Wurst W (2002) The
new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and
leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 42:297-303
van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker
D, Bardin PG (2005) Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates
allergen-induced asthmatic reactions. J Allergy Clin Immunol 116:292-298
Vestbo J, Tan L, Atkinson G, Ward J (2009) A controlled trial of 6-weeks' treatment with a novel
inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 33:1039-1044
Wang H, Edens NK (2007) mRNA expression and antilipolytic role of phosphodiesterase 4 in rat
adipocytes in vitro. J Lipid Res 48:1099-1107
Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, Cai J, Ke H (2007) Structures of
the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their
inhibitors. Biochem J 408:193-201
Weston MC, Anderson N, Peachell PT (1997) Effects of phosphodiesterase inhibitors on human
lung mast cell and basophil function. Br J Pharmacol 121:287-295
